Ignite Creation Date:
2024-05-06 @ 5:45 PM
Last Modification Date:
2024-10-26 @ 2:35 PM
Study NCT ID:
NCT05429216
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-07-01
First Post:
2022-06-17
Brief Title:
Endoscopic Resection for Small Rectal Neuroendocrine Tumors
Sponsor:
Nanfang Hospital Southern Medical University
Organization:
Nanfang Hospital Southern Medical University
Study Overview
Official Title:
Modified Cap-assisted Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection for Small Rectal Neuroendocrine Tumors Less Than 1 cm a Muticenter Randomized Noninferiority Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In previous single center study both modified cap-assisted endoscopic mucosal resection mEMR-C and endoscopic submucosal dissection ESD were reported to be effective for the treatment of small rectal neuroendocrine tumors NETs and mEMR-C was inferior to ESD for the treatment of small rectal NETs 10 mm as it has shorter operation times and lower hospitalization costs However a multicenter randomized controlled trial is needed to prove the universality and generality of these findings
Detailed Description:
Investigators aimed to conduct a muticenter randomized controlled trial to compare mEMR-C with ESD for the treatment of small rectal neuroendocrine tumors NETs in six tertiary hospitals in China
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None